Generic placeholder image

Letters in Drug Design & Discovery

Editor-in-Chief

ISSN (Print): 1570-1808
ISSN (Online): 1875-628X

Recent Advancement in the Field of Anticonvulsants: A Review

Author(s): Shailendra Pandey and Radhey Shyam Srivastava

Volume 7, Issue 9, 2010

Page: [694 - 706] Pages: 13

DOI: 10.2174/157018010792929487

Price: $65

Abstract

This study emphasized on the recent developments in the field of anticonvulsant agents. The review illustrates various structural classes of compounds which were evaluated for anticonvulsant action according to the established procedure by the Antiepileptic Drug Development Program of the Epilepsy Branch, National Institute of Neurological Disorders and Stroke, National Institute of Health, USA. This review encompasses some new anticonvulsant agents of various chemical structures, and for most of the compounds the precise mechanism of action is still not known. These newer agents include: tryptamines and isotryptamines, sulfonamides (carbonic anhydrase inhibitors), derivatives of amino acids, isoindolinedione derivatives, lactams and amides, quinazolin-4-(3H)-one derivatives, γ-hydroxybutyric acid (GHB) and its derivatives, semicarbazones and thiosemicarbazones. These new compounds of different structural classes could be handy for designing the future targets and in the determination of their precise mechanism of action. Nevertheless, few new drugs have brought significant advancement in the tolerability of anticonvulsant therapies. This study would be useful to design novel, effective anticonvulsant to combat epilepsy in its numerous forms, with more selective activity and least toxicity.

Keywords: Anticonvulsant agent, Epilepsy, Maximal Electroshock Seizure, Pentylenetetrazole, Antiepileptic Drug, Neurological Disorders, Tryptamines, Isotryptamines, Semicarbazones, Thiosemicarbazones, Mono-therapy, Ionotropic, Glutamate receptors, Gabapentin, Vigabatrin, Felbamate, Lamotrigine, Oxcarbazepine, Tiagabine, topiramate, Second generation drugs, Third generation drugs, Human clinical trials, Pharmaco resistant, Fluoxetine, Serotonergic neurotransmitters, 5-HT, Neurotransmitters, Hyperpolarization, Aromatic core, Tricyclic indoles, Non-inactivating currents, Extracellular serotonin, Audiogenically-evoked seizures, Aza-spiranes, Maximal electroshock seizures (MES), 5-dione ring, N-salicy loyltryptamine (NST), Brain enzymes, GABAergic transmission, Benzothiazole molecules, Phenylacetic acid, Neurotoxicity, Sulfonamide CA inhibitors, Isoindolinone, Isoindolinedione Derivatives, Thaliclomide, Lactam, Amides Derivatives, Pharmacodynamic activity, Neurotoxic effects, Micro-molar, Valproic acid, (α-valerolactam), (caprolactam), Bicuculline, Picrotoxin, Strychnine picrotoxin - induced seizures, (GHB), Functionalized amino acids (FAA), Aminomethyl linker, Neuropathic pain, Allosteric Modulators, γ-aminobutyric acid, Antidepressant activity


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy